Moshe Chaim Ornstein

Also affiliated with Cancer Institute (WIA)

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 8 papers. Top paper: “Molecular Genetic Determinants of Shorter Time on Active Surveillance in a Prospective Phase 2 Clinical Trial in Metastatic Renal Cell Carcinoma”.

Molecular Genetic Determinants of Shorter Time on Active Surveillance in a Prospective Phase 2 Clinical Trial in Metastatic Renal Cell Carcinoma

European Urology(2021)10.1016/j.eururo.2021.12.003

N/A

0.396DataRank · unranked

13 citations

Akhilesh Mishra, Alana Christie, Tiffani McKenzie, Oreoluwa Onabolu, Nirmish Singla +12 more

Prognostic value of integrated liquid biopsies in patients (pts) with metastatic urothelial cancer (mUC).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.6_suppl.547

N/A

0.104DataRank · unranked

1 citations

Hamid Emamekhoo, Katherine R. Kaufmann, Petros Grivas, Moshe Chaim Ornstein, Iris Yeong- Fung Sheng +9 more

Treatment-free survival (TFS) outcomes from the phase II study of nivolumab and salvage nivolumab + ipilimumab in advanced clear cell renal cell carcinoma (aRCC) (HCRN GU16-260-Cohort A).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.6_suppl.604

N/A

0DataRank · unranked

5 citations

Opeyemi A. Jegede, David F. McDermott, Naomi B. Haas, Mehmet Asım Bilen, Mark N. Stein +11 more

Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2023-008293

N/A

0DataRank · unranked

6 citations

Opeyemi A. Jegede, Naomi B. Haas, David F. McDermott, Mehmet Asım Bilen, Mark N. Stein +11 more

Phase 1b/2 study of batiraxcept alone and in combination with cabozantinib with or without nivolumab for advanced clear cell renal cell carcinoma

The Oncologist(2025)10.1093/oncolo/oyaf138

N/A

0DataRank · unranked

0 citations

Neil J. Shah, Matthew T. Campbell, Naomi B. Haas, Ariel Ann Nelson, Moshe Chaim Ornstein +12 more

Clinical Outcomes of Platinum-ineligible Patients with Advanced Urothelial Carcinoma Treated With First-line PD1/L1 Inhibitors

Clinical Genitourinary Cancer(2021)10.1016/j.clgc.2021.04.008

N/A

0DataRank · unranked

38 citations

Archana M. Agarwal, Moshe Chaim Ornstein, Jorge García, Ruby Gupta, Petros Grivas +11 more

Trimodality Therapy for Bladder Cancer: A Single Institution Retrospective Analysis of Factors Associated With Outcomes for High-Risk Patients Undergoing Organ-Sparing Therapy

Clinical Genitourinary Cancer(2025)10.1016/j.clgc.2025.102477

N/A

0DataRank · unranked

0 citations

Jessica Scarborough, C.A. Reddy, A. Bommireddy, Erin F. Brooks, Nima Almassi +12 more

Transcriptomic Features of Cribriform and Intraductal Carcinoma of the Prostate

European Urology Focus(2022)10.1016/j.euf.2022.05.005

N/A

0DataRank · unranked

12 citations

Tarik Benidir, Magdalena A. Rainey, Monica Nair, Elai Davicioni, Ewan A. Gibb +9 more